Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
@article{Lieberman2005EffectivenessOA, title={Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.}, author={Jeffrey A. Lieberman and T. Scott Stroup and Joseph P. McEvoy and Marvin S. Swartz and Robert A. Rosenheck and Diana O. Perkins and Richard S. E. Keefe and Sonia M. Davis and Clarence E. Davis and Barry Lebowitz and Joanne B. Severe and John K. Hsiao}, journal={The New England journal of medicine}, year={2005}, volume={353 12}, pages={ 1209-23 } }
BACKGROUND
The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. [] Key MethodRESULTS
Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to…
5,024 Citations
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
- Medicine, PsychologySchizophrenia Research
- 2009
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- Psychology, MedicineThe Lancet
- 2008
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
- Psychology, MedicineThe American journal of psychiatry
- 2007
Among this group of patients with chronic schizophrenia who had just discontinued the older antipsychotic perphenazine, quetiapine and olanzapine were more effective than risperidone, as reflected by longer time to discontinuation for any reason.
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
- Psychology, MedicineThe American journal of psychiatry
- 2006
Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.
Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders
- Medicine, PsychologyJournal of psychopharmacology
- 2010
It is concluded that there is a very high rate of discontinuation of the initial antipsychotic medications for various reasons, with risperidone having an overall longer time to discontinuation compared with first-generation antipsychotics medications.
Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
- Medicine, PsychologyNeuropsychiatric disease and treatment
- 2011
Aripiprazole may be considered the best available option for long-term treatment of patients with schizophrenia or schizoaffective disorder because of the time to discontinuation of each second-generation antipsychotic.
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
- Psychology, MedicineJournal of psychiatric research
- 2006
Ann schizophrenia-spectrum disorders Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with
- Medicine, Psychology
- 2010
It is concluded that there is a very high rate of discontinuation of the initial antipsychotic medications for various reasons, with risperidone having an overall longer time to discontinuation compared with first-generation antipsychotics medications.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
- Psychology, Medicine
- 2006
If there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason, this randomized, double-blind study compared them in patients who had just discontinued a different atypical antipsychotic.
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
- Psychology, MedicinePsychopharmacology
- 2011
The efficacy of seven antipsychotic medications for the maintenance treatment appeared similar in early-stage schizophrenia, and special programs are needed to keep efficacy and safety of antipsychotics maintenance treatment for schizophrenia with early stage schizophrenia.
References
SHOWING 1-10 OF 40 REFERENCES
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
- Psychology, MedicineJAMA
- 2003
Olanzapine does not demonstrate advantages compared with haloperidol (in combination with prophylactic benztropine) in compliance, symptoms, extrapyramidal symptoms, or overall quality of life, and its benefits in reducing akathisia and improving cognition must be balanced with the problems of weight gain and higher cost.
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
- Psychology, MedicineMolecular Psychiatry
- 2005
A brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotic drugs is provided, and focuses on novel targets for therapeutic agents for future drug development.
Dose Response and Dose Equivalence of Antipsychotics
- Medicine, PsychologyJournal of clinical psychopharmacology
- 2004
Evidence from randomized, placebo-controlled studies of patients with schizophrenia or schizoaffective disorder, which compared 2 or more doses of an antipsychotic to calculate the dose-response curve is reviewed to find 3.3 to 10 mg haloperidol to be the near-maximal ED range.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
- Medicine, PsychologyThe Lancet
- 2003
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
- Psychology, MedicineThe New England journal of medicine
- 2002
Adult outpatients with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if they are treated with risperidone than if they were treated with haloperidol.
Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials
- Psychology, MedicineSchizophrenia Research
- 2002
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
- Psychology, MedicineArchives of general psychiatry
- 1988
In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
- Medicine, Psychology
- 2003
Some SGAs are more efficacious than FGAs, and, therefore,SGAs are not a homogeneous group, as suggested by consensus panel recommendations.
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
- Psychology, MedicineThe American journal of psychiatry
- 2001
It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate.
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
- Medicine, PsychologyArchives of general psychiatry
- 2002
A strong association between olanZapine exposure and hyperlipidemia in schizophrenic patients is observed and the possible metabolic consequences of olanzapine use should be given serious consideration by treating physicians.